Announcements Trials

Browse Landscape

Phase

Phase 2 7 Phase 3 4 Phase NA 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 627 pembrolizumab 506 Paclitaxel 455 Gemcitabine 439 Carboplatin 438 Cisplatin 421 Radiotherapy 382 fludarabine 368 Nivolumab 340 Docetaxel 278 Bevacizumab 276 Irinotecan 258 Magnetic Resonance Spectroscopy 246 Fluorouracil 229 Dexamethasone 225 Specimen Handling 224 Capecitabine 218 Rituximab 206 Oxaliplatin 201 Cytarabine 201 Biopsy 198 Temozolomide 197 Ipilimumab 197 fludarabine phosphate 195 Etoposide 181 Lenalidomide 176 Doxorubicin 175 Leucovorin 174 Injections 171 Cetuximab 171

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Interventional × L-BLP25 × Clear all

NCT01731587 2017-02-28

FINGERPRINT

Merck KGaA, Darmstadt, Germany

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡